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Single	cell	sequencing	to	identify	TCRs	that	recognize	autologous	tumor	
cells	after	vaccination	with	allogeneic	DRibble	vaccine	(DPV-001)		
Background	Adoptive	immunotherapy	with	tumor-specific	TCR	gene-modified	T	cells	has	the	potential	to	eradicate	bulky	disease.	Traditional	methods	of	TCR	
identification	require	lengthy	in	vitro	culture	to	generate	clonal	T-cell	populations,	which	adds	time	and	complexity	to	this	promising	therapy.	Here	we	described	
a	 simplified	 and	 reliable	method	 to	 identify	 TCRs	 by	 single	 cell	 TCR	 sequencing	 of	 cells	 sorted	 with	 antibodies	 against	 T-cell	 surface	markers	 that	 are	 up-	
regulated	only	when	they	are	stimulated	with	specific	tumor	cell	antigens.		
Materials	and	Methods	A	tumor-infiltrating	lymphocyte	(TIL)	culture	with	T	cells	reactive	against	autologous	tumor	was	generated	from	a	brain	metastasis	of	a	
patients	with	NSCLC	(UbiLT-002).	A	panel	of	antibodies	against	T-cell	surface	antigens	was	screened	to	identify	markers	that	are	specifically	up-regulated	after	
stimulation	with	autologous	tumors	but	not	with	related	allogeneic	tumor	cells.	Tumor-reactive	T	cells	were	sorted	from	TIL	with	three	suitable	antibodies	and	
expanded	by	a	rapid	expansion	protocol.	Expanded	T	cells	were	examined	for	their	tumor-specificity	and	subjected	to	single	cell	TCR	sequencing	using	the	10X	
genomic	system.	The	top	10	TCRs	were	identified	by	bio-	informatics	approach	and	the	corresponding	alpha	and	beta	chains	were	synthesized	and	cloned	into	a	
retroviral	 vector	based	on	MSG	backbone.	PBMC	 from	healthy	donors	were	 transduced	with	 the	 retrovirus	 supernatant	after	activation.	Tumor-reactivity	of	
transduced	T	cells	was	determined	after	expansion	in	media	supplemented	with	IL-2,	IL-7,	and	IL-15.	To	identify	tumor-reactive	TCRs	in	PBMC	from	the	same	
patient	 after	 vaccination	with	 an	 off-the-shelf	 allogeneic	 proteasome-blocked	 autophagosome	 vaccine	 (DPV-001,	 UbiVac),	 we	 also	 developed	 a	 protocol	 to	
expand	tumor-specific	T	cells	from	PBMC	with	in	vitro	stimulation	with	DPV-001	vaccine-loaded	PBMC.		
Results	We	identity	CD94,	CD137(4-1BB),	CD355	(CRTAM)	as	specific	markers	for	antigen-specific	activation	of	T-cells	by	autologous	tumor	cells,	whereas	other	
"check	 point"	 markers	 such	 as	 CTLA-4,	 PD-1,	 Tim3,	 CD39,	 CD103	 were	 up-regulated	 by	 stimulation	 with	 unrelated	 tumor	 cells.	 These	 antibodies	 were	
successfully	used	to	sort	and	enrich	tumor-specific	T	cells.	The	top	10	TCRs	from	each	sorting	were	different	but	with	overlapping	clones.	Five	TCR	clones	were	
tumor-specific	and	capable	to	recognize	the	autologous	tumor	cells	when	they	were	expressed	on	T-cells	 from	health	donors.	Additionally,	ex-vivo	culture	of	
vaccine	stimulated	PBMC	from	a	post-vaccine	timepoint	generated	T	cells	enriched	for	activity	against	autologous	tumor.		
Conclusions	We	developed	a	simplified	work	flow	to	identify	tumor-specific	TCRs.	This	flow	will	be	further	improved	with	antibody	with	DNA	bar	codes	and	used	
to	identify	tumor-reactive	TCRs	in	a	streamlined	fashion.	Trial	Registration	NCT01909752	
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Conclusions,	Future	Plans	And	Comments	On	Development	Of	Combination	Immunotherapy			
•  We	have	developed	a	simplified	work	flow	to	identify	tumor-reactive	TCRs	and	are	applying	this	to	study	vaccine-induced	
autologous	tumor-reactive	T	cells	in	the	peripheral	blood.		
•  These	TCRs,	particularly	those	induced	to	common	shared	cancer	antigens,	may	be	useful	for	TCR	gene	therapy	of	NSCLC.	
•  This	approach	may	be	improved	by	incorporating	DNA	bar-coded	mAbs	to	identify	tumor-reactive	T	cells	and	corresponding	TCRs.	
•  While	clinical	trials	of	T	cell	agonists	have	been	largely	disappointing	as	single	agents	or	combined	with	checkpoint	blockade,	
preclinical	studies	suggest	that	T	cell	agonists,	like	anti-OX40	and	anti-GITR,	can	augment	and	sustain	vaccine-induced	therapeutic	
anticancer	responses	(Yu,	G.	et	al.,	Sci	Rep	2016).		
•  Even	without	fully	characterizing	the	functional	activity	of	a	specific	TCR,	the	identification	of	TCRs	of	T	cells	that	upregulate	
expression	of	CRTAM,	4-1BB	or	CD94	following	exposure	to	autologous	tumor,	provides	a	novel	approach	to	monitor	persistence	
and	expansion	of	tumor-reactive	T	cells	using	TCR	analysis.	
•  This	strategy	will	be	useful	to	assess	the	impact	of	immunotherapy	agents	on	expansion	and	survival	of	these	cells	–	An	objective	
put	forward	by	the	FDA		(https://www.fda.gov/Drugs/NewsEvents/ucm562746.htm)	
Figure	2.	TIL	from	UBLT002	were	assessed	and	sorted	for	antigen	specificity	towards	autologous	tumor.	A)		Schema	for	cell	isolation.		B)	4-1BB,	
CRTAM	and	CD94	are	markers	for	antigen-specific	activation	of	TIL101	by	LT101	autologous	tumor	cells	but	not	allo	tumors	LT36	or	Mel1383.	
1383l	are	TIL	autologous	to	Mel1383,	showing	that	this	tumor	is	capable	of	stimulating	an	Ag-specific	response.	C)	Other	markers	of	antigen	
activation	did	not	confer	the	specificity	seen	in	A.	D	and	E)	LT101	cells	were	co-cultured	with	LT101	for	24hrs	prior	to	sorting	for	4-1BB,	CRTAM	
and	CD94	CD8	T	cells.	After	expansion,	rest	and	restimulation,	these	populations	were	enriched	for	Ag-specific	expression	of	those	same	
markers	(D)	but	not	other	markers	associated	with	activation	(E).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
CD94,	CD137(4-1BB),	CD355	(CRTAM)	as	Markers	for	Antigen-Specific	Activation	of	T-cells	by	Autologous	Tumor	Cells	
	
	
	
	
	
	
	
Top	TCRs	From	Each	Sorting	Were	Different	But	With	Overlapping	Clones	
Figure	5.	Baseline	and	week	12	PBMC	from	
DPV-001-vaccinated	NSCLC	patient	were	
stimulated	ex-vivo	with	DPV-001	(or	not	–	
neg	control)		for	24	hours	prior	to	expansion	
for	11	days	on	IL2	and	IL15.	Cells	were	
harvested	and	restimulated	with	autologous	
tumor	or	no	stimulus	(neg)	and	anti-CD3	
(pos)	controls.	24	hour	cytokine	secretion	
assessed	with	cytokine	bead	array.	Mean	
and	SEM	of	experimental	nonuplets	
(primary	stim	triplicates	divided	into	
secondary	stim	triplicates)	shown.	
	
Figure	3.	CDR	of	TCR𝛽	chains	for	LT101	and	
associated	Ag-specific	sorted	populations	
were	assessed	using	Adaptive	
Biotechnologies	immunoSEQ.	The	graph	
sorts	clones	by	the	most	numerous	within	
the	original	TIL101.	Heat	mapping	of	the	
TIL101	and	sorted	populations	illustrate	the	
most	numerous	(red)	and	least	numerous	
(green)	clones	within	each	column.	The	top	
CRTAM	sorted	clones	were	assessed	for	
single	cell	gene	expression	of	immune	
receptors	using	10X	Genomics	Chromium.	
The	last	column	associates	the	CDR	of	TCR𝛽	
chains	with	TCR	used	to	transfect	Jurkat	
reporter	cells	(figure	4).		
	
TCR101.1,	TCR101.2	and	TCR101.5	share	
the	same	𝛽	chain	CDR.	TCR101.1	has	a	
unique	α	chain	while	TCR101.2	and	
TCR101.5	share	the	same	α	chain	CDR.		
		
	
		
Four*	TCR	Clones	Were	Tumor-reactive	And	Capable	To	Recognize	The	Autologous	Tumor	Cells	
When	They	Were	Expressed	By	Jurkat	T	Cells	
Figure	4.	Transduced	Jurkat	
reporter	cells	(>60%	express	the	
TCR)	were	stimulated	with	LT101	
tumor	cells	or	panc48	cells	for	18	
hours.	Jurkat	cell	alone	were	used	
as	the	negative	control.	The	
luciferase	activity	in	the	
supernatant	was	determined	by	
luciferase	assay.	The	9	mer	TCR	
(from	Dr.	Eric	Tran)	recognizes	the	
mutant	Kras	epitope	presented	by	
HLA-C0802.	
	
*			Two	TCRs	were	identical	–	Only	4	
					unique	TCRs	
	
DPV-001	Vaccination	Primes/Boosts	Polyfunctional	T	Cells	That	Recognize	Autologous	Tumor	Cells		
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A.	
D.	 E.	
B.	
Amino Acid CD137 CD94 CRTAM TIL101 TCR 101.
CASSQGTEAFF 0.155606 0.007985 0.136015 19.605097
CASTPGWNTEAFF 0.068467 0.071869 0.075855 8.19213
CASSSLAGGVYEQYF 0 0 0 4.740232
CSAWGAREASYEQYF 0 0 0 3.248845
CASGIRASQETQYF 0 0 0 2.835737
CASNPAPTANYGYTF 0 0 0.007847 2.814732
CASSLLAGGSDTQYF 6.940036 33.201573 36.922916 2.57667 1, 2, 5
CASSYVGANVLTF 14.328217 0.027949 0.496979 2.401624
CASSLSTGLHYNEQFF 0 0 0 2.128553
CASSQGRTIYF 0.069712 0.127767 0.214486 2.107548
CASRDFSSYEQYF 0 0 0 1.981515
CASSEGTVVSGANVLTF 0 0 0 1.981515
CASSIAGPSYNEQFF 0 0 0.023541 1.855482
CASSSGTPSGTYSNQPQHF 31.280577 0.007985 8.5585 1.638426 9
CASSSRGANYGYTF 0 0 0 1.358353
CASRDSGIAYGYTF 0 0 0 1.30934
CASSLRGGETQYF 0 0 0 1.225319
CASSSSYGEQYF 0 0 0 1.141297
CASSVAGAGDTQYF 2.031594 2.10417 2.963564 1.134295
CASSLSVEYEQYF 0 0 0 1.127293
CASSLDGGDTQYF 0 0 0 1.127293
CAISEPQRGVYEQYF 0 20.147332 0.347885 1.092284
CASSPLSGYEQYF 0.017428 0 0 1.022266
CASSFLGGHTGELFF 0.001245 0 0 0.861224
CASRTGTAYNEQFF 3.138265 0 0.627763 0.784204
CSVLVAARAYEQYF 0 0.221597 0 0.7702
CSARGLAGIINSYEQYF 0 0 0 0.735191
CASSEDRSYGYTF 0 0 0.196176 0.721188
CASSLTGTNYNEQFF 0.03859 0 0.873637 0.714186
CASSTRDSPTDTQYF 0.001245 0.301451 0.002616 0.69318
CASSLTGLYYNEQFF 0 0.151724 2.696764 0.61616
CASSLTSGSYNEQFF 0 0 0 0.609158
CASSQNRQMNTGELFF 0 0 7.875808 0.46212 7
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